Why the study?
Clinical and pathophysiological data regarding the use of zotarolimus-eluting stents for coronary artery disease require comprehensive review.
Does zotarolimus-eluting stent improve outcomes in patients with coronary artery disease?
Does zotarolimus-eluting stent improve outcomes in patients with coronary artery disease?
Zotarolimus-eluting stents are safe for treating coronary artery disease, though early generations were less effective at preventing restenosis than competitors, with newer generations showing potential for improvement.
May favor sirolimus- or paclitaxel-eluting stents to reduce restenosis; leaves open efficacy of subsequent zotarolimus generations.
BACKGROUND: Zotarolimus is an anti-proliferative drug used exclusively in the design of coronary drug eluting stent. OBJECTIVE: To review pathophysiological and clinical data regarding the use of zotarolimus-eluting stent (ZES) for the treatment of coronary artery disease. METHODS: Mechanism of action of zotarolimus is reviewed and design of different type of ZES described. Clinical results of the trials by the use of different ZES are discussed. RESULTS: First and second generations of ZES demonstrated to be safe but less effective in preventing restenosis as the competitive sirolimus eluting stent and paclitaxel eluting stent. Third generation of ZES that show new pharmacokinetic release of the drug may improve clinical results in continuing trials. CONCLUSIONS: Zotarolimus incorporated on stent platform represents a useful tool in treating patients with coronary artery disease. Release kinetic of the drug may play a major role in in-stent neointimal suppression during follow-up.
No takes yet. Share an insight, caveat, or question.
Brugaletta et al. (2009) conducted a review in Coronary artery disease. Zotarolimus-eluting stent (ZES) vs. Sirolimus-eluting stent and paclitaxel-eluting stent was evaluated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: